Aims Sulphonylurea use has been linked with increased cardiovascular disease risk;
however, previous studies have been inconsistent. Type 2 diabetes independently …

We conducted a meta-analysis of cohort and case-control studies to evaluate all-cause and
cardiovascular (CV) mortality of patients with type 2 diabetes mellitus (T2DM) who received …

Recent randomized trials have compared the newer antidiabetic agents to treatments
involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality …

More than 40 years after publication of the U niversity G roup D iabetes P rogram trial, the
cardiovascular safety of sulphonylureas is still contentious. Although several hypotheses …

Aims To evaluate the risk of all‐cause mortality and major adverse cardiovascular events
(MACE) for patients exposed to first‐line monotherapy with sulphonylurea or metformin …

Aim Cardiovascular safety of sulfonylurea has been questioned by some authors. This
article aims at collecting all available data on this issue from randomized trials. Methods A …

Background Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes.
There is conflicting data about the safety of these drugs regarding mortality and …

Aims Sulfonylureas are recommended as second‐line treatment in the management of type
2 diabetes. However, they are still commonly used also as first‐line treatment instead of …

Background Sulfonylureas are common second-line options for management of type 2
diabetes; however, they are associated with a higher risk of cardiovascular events compared …

Aim To conduct a systematic review and meta‐analysis to determine the risk of
cardiovascular events and all‐cause mortality associated with sulphonylureas (SUs) vs …